Ff-7, Raj Iconza, Opp. Vinte Villa, Kudasan, Gandhinagar, Gujarat, India +91 7016957675
Uncategorized

10 Regulatory Documentation Mistakes That Delay Approval

When a regulatory submission runs into delays, the first suspect is usually the science. In practice, much of the friction comes from the documents themselves: summaries that don’t make the case, numbers that differ between sections, and statements a reviewer can’t trace back to data. Each of these can lead to questions from FDA, EMA […]

Uncategorized

Regulatory Inspection Readiness: 9-Step Document Checklist

An inspection is rarely lost on the day. It is lost in the months before, when documents drift out of step with each other, procedures stop matching what people actually do, and nobody checks. Inspectors from FDA, EU member states and MHRA know that no organization is perfect. Deviations happen. What they look for is […]

Uncategorized

CSV vs CSA: What the FDA’s Computer Software Assurance Guidance Means for Your Validation Programme

A clear breakdown of the shift from traditional Computer System Validation (CSV) to the FDA’s newer Computer Software Assurance (CSA) framework — what changed, what stayed the same, and how to practically adapt your validation programmes. Ideal for IT compliance managers and quality professionals responsible for GxP system validation.

Uncategorized

GMP Inspection Readiness: What FDA and EMA Inspectors Actually Look For in 2025

An in-depth look at the most common observations from recent FDA 483s and EMA GMP deficiency reports — with practical guidance on how companies can proactively address gaps before inspectors arrive. Covers data integrity, CAPA quality, training records, and SOP management. Written for quality directors and site heads at pharmaceutical manufacturing facilities.

Uncategorized

How Medical Writing Improves Regulatory Approval Rates — And What Most Companies Get Wrong

A practical guide exploring how the quality of regulatory documentation directly affects submission review timelines and approval outcomes. Covers common errors in CSRs and CTD narratives, the cost of poor documentation, and what review-ready documents actually look like. Ideal for regulatory affairs managers and CMC teams at mid-size pharma companies preparing for NDA or MAA […]

Need Help?